Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Christopher P Venner, MD, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J White, MD, Andrew Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Marc Lalancette, MD FRCP, Martha L Louzada, MDMSc, Andrea Kew, MDFRCP(C), Arleigh McCurdy, MD, Tony Reiman, MD, Max Sherry, Gail T. McDonald, Bethany Elaine Monteith, MD, Engin Gul, BS, MBA, Bingshu E. Chen, Annette E. Hay

Blood (2019) 134 (Supplement_1): 1871.

https://doi.org/10.1182/blood-2019-122637

Published: 2019

Journal Articles

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Michael Sebag, MD PhD, Nizar Bahlis, MD, Christopher P. Venner, Arleigh McCurdy, MD, C. Tom Kouroukis, MDMSc,FRCPC, Jesse Shustik, MD, Darrell J White, MD, Rami Kotb, MD, Julie Stakiw, MD, Nicole B. Laferriere, MD PhD, Tony Reiman, MD, Fernando Camacho, Julia Dobbin, Molei Fu, Engin Gul, BS, MBA, Donna E Reece, MD

Blood (2019) 134 (Supplement_1): 3121.

https://doi.org/10.1182/blood-2019-124457

Published: 2019

Journal Articles

Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens

Donna E Reece, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD, Kevin Song, MD, Michael Sebag, MD PhD, Richard Leblanc, MDFRCPC, Martha L Louzada, MDMSc, Darrell J White, MD, Julie Stakiw, MD, Tony Reiman, MD, Rami Kotb, MD, Muhammad Aslam, MD, Engin Gul, BS, MBA, Christopher P Venner, MD

Blood (2019) 134 (Supplement_1): 1886.

https://doi.org/10.1182/blood-2019-125479

Published: 2019

Journal Articles

Treatment of Myeloma Patients Progressing on Lenalidomide-Based Maintenance after ASCT Performed As Part of 1 st , 2 nd or 3 rd Line Therapy: Real-World Results from the National Myeloma Canada Research Network (MCRN) Database

Donna E Reece, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Victor Jimenez-Zepeda, MD, Arleigh McCurdy, MD, Kevin Song, MD, Richard Leblanc, MDFRCPC, Michael Sebag, MD PhD, Darrell J White, MD, Hannah Cherniawsky, BSc,MD, Tony Reiman, MD, Julie Stakiw, MD, Martha L Louzada, MDMSc, Rami Kotb, MD, Muhammad Aslam, MD, Engin Gul, BS, MBA, Christopher P Venner, MD

Blood (2019) 134 (Supplement_1): 3173.

https://doi.org/10.1182/blood-2019-125810

Published: 2019

Journal Articles

Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database

Victor Jimenez-Zepeda, MD, Donna E Reece, MD, McCurdy R Arleigh, MD MHA, FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, MSc, P.Stat, Michael Sebag, MD PhD, Julie Stakiw, MD FRCPC, Kevin Song, MD, Richard Leblanc, MDFRCPC, Tony Reiman, MD, Martha L Louzada, MD, Rami Kotb, MD, Engin Gul, BSc, Christopher P. Venner, MD FRCPC

Blood (2018) 132 (Supplement 1): 2008.

https://doi.org/10.1182/blood-2018-99-117363

Published: 2018

Journal Articles

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

Christopher P. Venner, MD FRCPC, Richard Leblanc, MDFRCPC, Irwindeep Sandhu, MDFRCPC, Darrell J. White, MD, Andrew R Belch, MD, Donna E Reece, MD, Christine I Chen, MD, Sean Dolan, MD, Andrea Kew, MDFRCP(C), Marc Lalancette, MD FRCP, Martha L Louzada, MD, Arleigh McCurdy, MD BSc, Gail T. McDonald, Tony Reiman, MD, Laura Rodriguez, Lois E. Shepherd, Engin Gul, BSc, Bingshu E. Chen, Annette E Hay

Blood (2018) 132 (Supplement 1): 1984.

https://doi.org/10.1182/blood-2018-99-117824

Published: 2018

Journal Articles

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Tony Reiman, MD, Kerry J. Savage, MD MSc, Michael Crump, MD, Matthew Cheung, MD, David A. MacDonald, MD, Rena Buckstein, MD, Stephen Couban, MD, Eugenia Piliotis, MD, Kevin R Imrie, MD, David Spaner, MD PhD, Sudeep Shivakumar, MD, John Kuruvilla, MD, Diego Villa, Lois E. Shepherd, MD, Tanya Skamene, MD, Chad Winch, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 4162.

https://doi.org/10.1182/blood.V128.22.4162.4162

Published: 2016

Journal Articles

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

Ming Han, BSc., Alli Murugesan, MSc, PhD, Nizar J Bahlis, MD, Kevin Song, Darrell White, MD MSc, FRCPC, FACP, Christine Chen, MD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Kang Howsen-Jan, MD, Donna Reece, Keith Stewart, MD, Yagang Xie, MD PhD FCCMG, Annette E Hay, MB ChB, Lois Shepherd, MD, Bingshu E Chen, PhD, Marina Djurfeldt, MSc., Tony Reiman, MD

Blood (2015) 126 (23): 2960.

https://doi.org/10.1182/blood.V126.23.2960.2960

Published: 2015

Journal Articles

Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma

Ethan Toumishey, B. Sc, Angeli Prasad, CCRP, Gregory S. Dueck, MD, MSc, BSc, FRCPC, Neil Chua, MD, FRCPC, Daygen Finch, MD, Douglas A. Stewart, MD, FRCPC, Darrell J. White, MD, Richard H. van der Jagt, MD, FRCPC, James B Johnston, MD, Andrew R Belch, MD, Tony Reiman, MD

Blood (2013) 122 (21): 4376.

https://doi.org/10.1182/blood.V122.21.4376.4376

Published: 2013

Journal Articles

A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial

A. Keith Stewart, Suzanne Trudel, MD, MSC, FRCPC, Nizar J Bahlis, MD, Darrell J White, MD, Waleed Sabry, MSc, MD, Andrew Belch, MD, Tony Reiman, MD, Jean Roy, MD, FRCPC, Chaim Shustik, MD, Michael J. Kovacs, MD, FRCPC, Jonathan Sussman, Ralph M. Meyer, MD, Erica L Harnett, M.Sc., Danila Oana, Judy A Chapman, Lois Shepherd, MD

Blood (2010) 116 (21): 39.

https://doi.org/10.1182/blood.V116.21.39.39

Published: 2010

Journal Articles

High Oct-2 Protein Expression Is Associated with Decreased Overall Survival, While High Bob-1 Protein Expression Is Associated with Improved Overall Survival in Myeloma Patients.

Inka Toman, M.Sc., Jonathan Loree, Alex Klimowicz, Ph.D., Nizar J Bahlis, MD, Raymond Lai, MD, PhD, Andrew Belch, MD, Linda M. Pilarski, PhD, Tony Reiman, MD

Blood (2009) 114 (22): 2822.

https://doi.org/10.1182/blood.V114.22.2822.2822

Published: 2009

Journal Articles

Comparative Whole Transcriptome Shotgun Sequencing (WTSS) of Myeloma at Diagnosis and at Drug-Resistant Relapse.

Tony Reiman, MD, Ryan Morin, PhD, Rodrigo Goya, Tina Wong, Yongjun Zhao, Martin Hirst, Linda M. Pilarski, PhD, Andrew Belch, MD, Marco Marra, PhD

Blood (2009) 114 (22): 603.

https://doi.org/10.1182/blood.V114.22.603.603

Published: 2009

Journal Articles

Epigenetic Regulation of the WNT Canonical Pathway in Mantle Cell Lymphoma.

Anthea C Peters, MD, MSc, Randy Chung, MD, Charles S Wong, Leah C Young, PhD, Tony Reiman, MD, Raymond Lai, MD, PhD

Blood (2008) 112 (11): 3340.

https://doi.org/10.1182/blood.V112.11.3340.3340

Published: 2008

Journal Articles

Silencing Immunoglobulin Gene Enhancers as a Potential Treatment Strategy for Multiple Myeloma

Inka Toman, Jonathan Loree, Kim Duerksen, MSc, Robert Evans, PhD, Tony Reiman, MD

Blood (2008) 112 (11): 5162.

https://doi.org/10.1182/blood.V112.11.5162.5162

Published: 2008

Journal Articles

Analysis of Protein Biology to Increase Efficacy of Aurora Kinase Inhibitors for Multiple Myeloma Therapy.

Robert P. Evans, Ph.D., Kim Laginha, Linda M. Pilarski, PhD, Andrew Belch, MD, Tony Reiman, MD

Blood (2008) 112 (11): 1699.

https://doi.org/10.1182/blood.V112.11.1699.1699

Published: 2008

Journal Articles

Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Sundar Jagannath, MD, Ravi Vij, MD, A. Keith Stewart, MBChB, George Somlo, MD, Andrzej Jakubowiak, MD, PhD, Tony Reiman, MD, Suzanne Trudel, MD, Jessica Taylor, BA, Diana Fuhrman, BSN, Scott Cruickshank, MS, Richard Schwartz, MD, Lori Kunkel, MD, David Siegel, MD, PhD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2008) 112 (11): 864.

https://doi.org/10.1182/blood.V112.11.864.864

Published: 2008

Journal Articles

Germline and Somatic Mutations in the Hyaluronan Synthase–1 (HAS1) Gene May Contribute to Oncogenesis in Multiple Myeloma (MM) and Waldenstrom’s Macroglobulinemia (WM).

Sophia Adamia, PhD, Amanda Reichert, Anirban Ghosh, Ph.D, Jennifer Hodges, Patrick Pilarski, Steven Treon, MD, Michael J. Mant, MD, Tony Reiman, MD, Andrew R. Belch, MD, Linda M. Pilarski, Ph.D

Blood (2007) 110 (11): 2488.

https://doi.org/10.1182/blood.V110.11.2488.2488

Published: 2007

Journal Articles

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Tony Reiman, MD, Daygen Finch, MD, Neil Chua, MD, Darrell White, MD, Douglas A. Stewart, MD, Richard van der Jagt, MD, James Johnston, MD, Angeli Prasad, Henry Schwarz, Jerome Zeldis, MD, Andrew R. Belch, MD

Blood (2007) 110 (11): 2579.

https://doi.org/10.1182/blood.V110.11.2579.2579

Published: 2007

Journal Articles

Pre-Clinical Validation of Polo-Like Kinase 1 as a Therapeutic Target in Multiple Myeloma with the Selective Inhibitor BI2536.

Roger Sidhu, MD, Tara Steffler, Gail Hipperson, Michelle Jung, Joyce Fung, Linda M. Pilarski, PhD, Andrew R. Belch, MD, Tony Reiman, MD, MSc

Blood (2007) 110 (11): 2514.

https://doi.org/10.1182/blood.V110.11.2514.2514

Published: 2007

Journal Articles

Genetic Polymorphisms Correlated with Outcome in Multiple Myeloma Patients Receiving High Dose Melphalan.

Charles Dumontet, MD, PhD, Stefano Landi, PhD, Tony Reiman, MD, PhD, Adriana Plesa, MD, Ilaria Bellini, PhD, Roberto Barale, PhD, Linda M. Pilarski, MD, Sean Tavtigian, PhD, Troy Perry, BsC, Federica Gemignani, PhD

Blood (2007) 110 (11): 4746.

https://doi.org/10.1182/blood.V110.11.4746.4746

Published: 2007

NARROW

Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens

Treatment of Myeloma Patients Progressing on Lenalidomide-Based Maintenance after ASCT Performed As Part of 1 st , 2 nd or 3 rd Line Therapy: Real-World Results from the National Myeloma Canada Research Network (MCRN) Database

Real-World Outcomes with Bortezomib-Containing Regimens and Lenalidomide Plus Dexamethasone for the Treatment of Transplant Ineligible MM Patients: A Multi-Institutional Report from the National Myeloma Canada Research Network (MCRN) Database

MCRN ¯ 003/MYX · 1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

Final Report Of a Phase II Clinical Trial Of Lenalidomide Monotherapy For T-Cell Lymphoma

A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial

High Oct-2 Protein Expression Is Associated with Decreased Overall Survival, While High Bob-1 Protein Expression Is Associated with Improved Overall Survival in Myeloma Patients.

Comparative Whole Transcriptome Shotgun Sequencing (WTSS) of Myeloma at Diagnosis and at Drug-Resistant Relapse.

Epigenetic Regulation of the WNT Canonical Pathway in Mantle Cell Lymphoma.

Silencing Immunoglobulin Gene Enhancers as a Potential Treatment Strategy for Multiple Myeloma

Analysis of Protein Biology to Increase Efficacy of Aurora Kinase Inhibitors for Multiple Myeloma Therapy.

Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Studyof Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)

Germline and Somatic Mutations in the Hyaluronan Synthase–1 (HAS1) Gene May Contribute to Oncogenesis in Multiple Myeloma (MM) and Waldenstrom’s Macroglobulinemia (WM).

First Report of a Phase II Clinical Trial of Lenalidomide Oral Therapy for Peripheral T-Cell Lymphoma.

Pre-Clinical Validation of Polo-Like Kinase 1 as a Therapeutic Target in Multiple Myeloma with the Selective Inhibitor BI2536.

Genetic Polymorphisms Correlated with Outcome in Multiple Myeloma Patients Receiving High Dose Melphalan.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only